A Director at Repros (NASDAQ: RPRX) is Selling SharesBy Carrie Williams
The company has a one year high of $3.48 and a one year low of $0.80. Currently, Repros has an average volume of 132.2K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
Repros Therapeutics, Inc. is a development stage company. The company operates as a biopharmaceutical company, which focuses on the development of new drugs to treat hormonal and reproductive system disorders. Its current product pipeline consists of Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in Woodlands, TX.